ev3 Inc. Appoints John K. Bakewell To Board Of Directors; Haywood D. Cochrane Steps Down From The Board
PLYMOUTH, Minn., April 5 /PRNewswire-FirstCall/ -- ev3 Inc. today announced that it has appointed John K. Bakewell to its board of directors, effective immediately. Bakewell will serve as chair of the audit committee of the board. ev3 also announced that, due to other professional commitments developing outside of ev3, Haywood D. Cochrane has stepped down from the board, also effective immediately.
Bakewell currently serves as executive vice president and chief financial officer of Wright Medical Group, Inc., a publicly held orthopaedic medical device company specializing in the design, manufacture and marketing of reconstructive joint devices and biologics products.
"John is a highly accomplished financial executive in the medical device industry who brings substantial financial operating expertise with public companies. John's expertise and insights will be valuable in helping to guide ev3's continued growth," said James M. Corbett, president and chief executive officer, ev3.
Prior to joining Wright Medical Group, Inc. in December 2000, Bakewell served as vice president of finance and administration and chief financial officer of Altra Energy Technologies, Inc., a software and e-commerce solutions provider to the energy industry, from July 1998 to December 2000. Bakewell served as vice president of finance and administration and chief financial officer of Cyberonics, Inc., a publicly held manufacturer of medical devices for the treatment of epilepsy and other neurological disorders, from May 1993 to July 1998.
Cochrane joined ev3's board early in 2005. "Haywood's participation and counsel on ev3's board of directors and audit committee was valuable, especially during our initial public offering process last year. We would like to thank Haywood for his dedicated service to ev3," said Corbett.
About ev3 Inc.
ev3 Inc. is a global medical device company focused on endovascular technologies for the minimally invasive treatment of vascular diseases and disorders.
Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Such potential risks and uncertainties relate, but are not limited, to, in no particular order: product demand and market acceptance; the impact of competitive products; and, pricing and success of clinical testing. More detailed information on these and additional factors which could affect ev3 Inc.'s operating and financial results are described in the company's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K. ev3 Inc. urges all interested parties to read these reports to gain a better understanding of the many business and other risks that the company faces. Additionally, ev3 Inc. undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.
ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S. and other countries.Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050615/CGEV3LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, email@example.com Inc.
CONTACT: Patrick Spangler, CFO of ev3 Inc., +1-763-398-7000,firstname.lastname@example.org